First-Line Therapy for CML-CP with Nilotinib or Dasatinib Compared to Imatinib and the Incidence of Treatment-Emergent BCR-ABL Mutations in Patients Who Received Nilotinib or Imatinib for CML-CP in the ENESTnd Trial


First-Line Therapy for CML-CP with Nilotinib or Dasatinib Compared to Imatinib and the Incidence of Treatment-Emergent BCR-ABL Mutations in Patients Who Received Nilotinib or Imatinib for CML-CP in the ENESTnd Trial
Slides from presentations at ASCO 2011 and comments from Susan M O’Brien, MD

Larson RA et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. Proc ASCO 2011;Abstract 6511.

Kantarjian HM et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the Phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12(9):841-51. Abstract

Dr O'Brien is Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.